BRIEF published on 12/17/2025 at 07:35, 1 month 14 days ago Sanofi publie son aide-mémoire pour le quatrième trimestre 2025 Sanofi Modélisation Financière Aide Mémoire 4e Trimestre 2025 Tourné Vers L'avenir
BRIEF published on 12/17/2025 at 07:35, 1 month 14 days ago Sanofi Releases Q4 2025 Aide Mémoire Sanofi Financial Modeling Aide Mémoire Q4 2025 Forward-Looking
BRIEF published on 12/17/2025 at 07:35, 1 month 14 days ago Sanofi publishes the document "Q4 2025 Quick Reference Guide" Financial Results Investors Sanofi Q4 2025 Modeling
BRIEF published on 12/17/2025 at 07:35, 1 month 14 days ago Sanofi publie le document « Q4 2025 Aide mémoire » Résultats Financiers Investisseurs Sanofi Modélisation Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 1 month 14 days ago Press release: Availability of the Q4 2025 Aide memoire Sanofi announces availability of Q4 2025 Aide memoire on the company's website for financial modeling purposes. Q4 2025 results to be published on January 29, 2026 Sanofi Results Aide Mémoire Financial Modelling Q4 2025
PRESS RELEASE published on 12/17/2025 at 07:30, 1 month 14 days ago Communiqué de presse : Mise en ligne du document «Q4 2025 Aide mémoire » Sanofi annonce la mise en ligne du document 'Q4 2025 Aide mémoire' pour assister la communauté financière dans la modélisation des résultats trimestriels Communication Financière Résultats Trimestriels Sanofi Document Q4 2025
BRIEF published on 12/15/2025 at 07:10, 1 month 16 days ago Sanofi : résultats de l'étude PERSEUS sur le tolébrutinib décevants Sclérose En Plaques Sanofi Tolebrutinib Étude PERSEUS Résultats D'étude
BRIEF published on 12/15/2025 at 07:10, 1 month 16 days ago Sanofi renonce à l'autorisation de mise sur le marché du tolebrutinib dans le traitement de la SEP progressive primaire Sclérose En Plaques Tolebrutinib Essai PPMS Étude PERSEUS Recherche Et Développement Chez Sanofi
BRIEF published on 12/15/2025 at 07:10, 1 month 16 days ago Sanofi: PERSEUS study results on tolebrutinib disappointing Study Results Multiple Sclerosis Sanofi Tolebrutinib PERSEUS Study
BRIEF published on 12/15/2025 at 07:10, 1 month 16 days ago Sanofi Halts Pursuit of Regulatory Registration for Tolebrutinib in PPMS Multiple Sclerosis Tolebrutinib PPMS Trial PERSEUS Study Sanofi R&D
Published on 01/31/2026 at 03:15, 16 hours 30 minutes ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 17 hours 25 minutes ago Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 18 hours 5 minutes ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 20 hours 45 minutes ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 3 hours 51 minutes ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 7 hours 20 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 17 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 21 hours 45 minutes ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 23 hours 35 minutes ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 1 day 2 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 1 day 2 hours ago Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 1 day 11 hours ago Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés
